Peripartum cardiomyopathy: diagnosis and heart failure management

Peripartum cardiomyopathy is an uncommon but potentially life-threatening form of heart failure associated with pregnancy. It usually appears during the final month of pregnancy or within the months after delivery, when symptoms can be mistaken for normal late-pregnancy discomfort or the demands of caring for a newborn.

The condition involves reduced left ventricular systolic function without another clear cause of heart disease. Early recognition matters because pulmonary edema, arrhythmia, thromboembolism, cardiogenic shock, and maternal death can develop rapidly. Recovery is possible, particularly when treatment begins before severe ventricular dysfunction becomes established.

Perinatal medicine depends on understanding the mother and infant as a connected clinical unit. The broader setting of maternal age, access to specialist care, pregnancy complications, and neonatal risk can influence outcomes, as illustrated by research on adolescent pregnancy outcomes across Oceania. A coordinated approach is therefore essential from the first concerning symptom through long-term follow-up.

What peripartum cardiomyopathy means

Peripartum cardiomyopathy is generally defined as idiopathic heart failure that develops toward the end of pregnancy or after delivery, accompanied by a left ventricular ejection fraction below 45%. The left ventricle may be dilated, although dilation is not required. The diagnosis is made after other causes of heart failure have been considered and excluded.

The underlying process is probably multifactorial. Abnormal vascular responses, inflammation, oxidative stress, autoimmune mechanisms, genetic susceptibility, and hormonal changes may all contribute. A biologically active prolactin fragment has also been investigated as a possible factor, although this pathway has not translated into a universally accepted treatment strategy.

Risk is higher with pre-eclampsia or gestational hypertension, multifetal pregnancy, advanced maternal age, African ancestry, previous peripartum cardiomyopathy, some tocolytic exposures, and certain cardiotoxic medications. A family history of dilated cardiomyopathy should prompt careful assessment for an inherited predisposition. Still, many patients have no obvious risk factor, so a low-risk history cannot replace clinical vigilance.

Recognizing the clinical pattern

Breathlessness, reduced exercise tolerance, orthopnea, paroxysmal nocturnal dyspnea, cough, and ankle swelling are common warning signs. Fatigue and palpitations may also occur. The important distinction is a change in severity, timing, or functional capacity that exceeds what would be expected in an uncomplicated pregnancy or normal postpartum recovery.

Physical findings can include tachycardia, raised jugular venous pressure, pulmonary crackles, an extra heart sound, hepatomegaly, and peripheral edema. Hypoxia, hypotension, confusion, cool extremities, or markedly reduced urine output suggest advanced hemodynamic compromise. Chest pain, a new murmur, or an irregular pulse should widen the assessment to include ischemia, valvular disease, and arrhythmia.

A high index of suspicion is particularly important after delivery. Patients may present weeks after discharge, when attention is focused on feeding and infant care. New breathlessness while lying flat, sudden weight gain, persistent cough, or repeated emergency visits for “anxiety” or fatigue should trigger cardiac evaluation rather than reassurance alone.

Confirming the diagnosis

Evaluation begins with vital signs, oxygen saturation, focused cardiovascular and respiratory examination, electrocardiography, chest imaging when indicated, and laboratory testing. B-type natriuretic peptide or N-terminal pro-BNP can support the diagnosis because these markers are usually much lower in uncomplicated pregnancy than in significant heart failure. Troponin may identify myocardial injury but is not specific for peripartum cardiomyopathy.

Transthoracic echocardiography is central. It assesses ejection fraction, chamber size, right ventricular function, valvular abnormalities, pulmonary pressures, intracardiac thrombus, and regional wall-motion changes. A reduced ejection fraction is clinically important even when symptoms appear modest. Serial echocardiograms help determine whether treatment is producing reverse remodeling.

The differential diagnosis includes pulmonary embolism, acute coronary syndrome or spontaneous coronary artery dissection, myocarditis, amniotic fluid embolism, pre-eclampsia-related pulmonary edema, congenital heart disease, tachycardia-mediated cardiomyopathy, and previously unrecognized dilated cardiomyopathy. Cardiac magnetic resonance imaging can be valuable when myocarditis or infiltrative disease is suspected, provided patient stability and pregnancy-related safety considerations are addressed.

Treating acute heart failure safely

Patients with pulmonary edema, severe hypoxia, hypotension, syncope, or evidence of poor perfusion require hospital care, often in a high-dependency or intensive care environment. Oxygen and ventilatory support may be needed. Intravenous loop diuretics relieve congestion, while careful fluid and electrolyte management helps avoid worsening renal dysfunction or hypotension.

During pregnancy, drug selection must account for fetal effects. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors are generally avoided before delivery because of fetal or neonatal risks. Hydralazine with a nitrate may provide an alternative after specialist review. Selected beta blockers can be used when clinically appropriate, with attention to maternal blood pressure, fetal growth, and neonatal bradycardia or hypoglycemia.

After delivery, guideline-directed therapy can usually expand. An ACE inhibitor such as enalapril is commonly considered compatible with breastfeeding, while other agents require individualized review. Beta blockade, mineralocorticoid receptor antagonism, and an SGLT2 inhibitor may be introduced according to blood pressure, renal function, potassium level, congestion, lactation plans, and local protocols. Diuretics should be titrated to symptoms and volume status rather than continued automatically at a high dose.

Thromboembolism deserves specific attention because pregnancy, the postpartum state, atrial fibrillation, intracardiac thrombus, and severely reduced ejection fraction can each increase risk. Low-molecular-weight heparin is often used during pregnancy, while postpartum anticoagulation depends on the individual risk profile. Bromocriptine, which suppresses lactation, has been studied in selected cases, but evidence remains limited and its use requires simultaneous consideration of thrombosis prevention and breastfeeding goals.

Planning delivery and postpartum care

Delivery timing and mode should be individualized by a multidisciplinary team involving maternal-fetal medicine, cardiology, anesthesia, neonatology, and nursing specialists. Hemodynamic stability, gestational age, ventricular function, response to therapy, and fetal condition all influence the plan. In a stable patient, vaginal birth is often preferred because it generally causes less blood loss and fewer abrupt hemodynamic changes than cesarean delivery.

Continuous or frequent monitoring may be appropriate for patients with significant ventricular dysfunction. Epidural analgesia can reduce pain-related stress and catecholamine surges, but it must be administered cautiously when blood pressure is marginal. Fluid administration should be conservative, and the immediate postpartum period deserves close observation because autotransfusion from the contracting uterus and mobilization of extracellular fluid can abruptly increase cardiac workload.

Discharge planning should include medication reconciliation, warning signs, blood pressure review, renal and electrolyte testing, and a scheduled cardiology appointment. Patients need clear instructions to seek urgent care for breathlessness at rest, fainting, chest pain, new confusion, rapid swelling, or inability to lie flat. Access to remote monitoring, telephone follow-up, and family support can be especially valuable during the first weeks at home.

Recovery, recurrence, and future pregnancy

Left ventricular function may improve substantially within the first year, but apparent recovery does not guarantee permanent resolution. Repeat echocardiography is commonly performed during treatment and at clinically important intervals. Persistent ejection fraction below 50% is associated with a higher risk of adverse outcomes and usually requires ongoing heart failure therapy.

A future pregnancy can lead to recurrent cardiomyopathy, particularly when ventricular function has not fully recovered. Preconception counseling should review the latest echocardiogram, medications, genetic and family history, contraception, and the patient’s reproductive priorities. Drugs that are unsafe in pregnancy need to be stopped or changed before conception under specialist supervision, and pregnancy should be followed in a center experienced in high-risk cardiac care.

Reliable contraception is part of treatment rather than an afterthought. Long-acting reversible methods may be suitable for many patients, while estrogen-containing options may be inappropriate when thrombosis risk or severe heart failure is present. Counseling should also address breastfeeding, mental health, sleep deprivation, physical rehabilitation, and the practical burden of long-term medication adherence.

The scientific and clinical context surrounding perinatal heart disease is reflected in the archived FAOPS 2020 congress site, which documented a major meeting focused on perinatal and neonatal medicine. Although the planned Tokyo congress was canceled during the COVID-19 pandemic, the need for collaboration across obstetrics, cardiology, neonatology, and research remains especially relevant to peripartum cardiac care.

Priorities for safer clinical practice

A consistent pathway can reduce delays between symptom onset and specialist treatment. The following principles help clinicians and families act decisively:

• Treat unexplained or disproportionate postpartum breathlessness as a possible cardiac symptom, not simply normal recovery.
• Arrange prompt echocardiography when heart failure is suspected, especially if natriuretic peptides are elevated or examination is abnormal.
• Use pregnancy-compatible therapy before delivery and transition to comprehensive heart failure treatment postpartum when appropriate.
• Involve cardiology, maternal-fetal medicine, anesthesia, and neonatology early in patients with significant ventricular dysfunction.
• Provide documented follow-up, contraception counseling, repeat imaging, and a preconception plan before any future pregnancy.

Peripartum cardiomyopathy demands speed, precision, and continuity. Recognizing the pattern early, confirming ventricular dysfunction, protecting the fetus when pregnancy continues, and delivering evidence-based heart failure care can change the course of illness. Clinicians, patients, and families can use established perinatal and cardiology resources to identify warning signs, coordinate specialist review, and support recovery from the first concern through long-term follow-up.